The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway

• Main Authors: Shuhan Liu (Author), Shengxiang Wang (Author), Runze Gu (Author), Na Che (Author), Jing Wang (Author), Jinbo Cheng (Author), Zengqiang Yuan (Author), Yong Cheng (Author), Yajin Liao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Exportin 1 (XPO1) is an important transport receptor that mediates the nuclear export of various proteins and RNA. KPT-8602 is a second-generation inhibitor of XPO1, demonstrating the lowest level of side effects, and is currently in clinical trials for the treatment of cancers. Previous studies sug...